Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

Recruiting

Phase 3

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic EsophagitisEfficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

Sponsor:

AstraZeneca

Code:

NCT05583227

Conditions

Eosinophilic Esophagitis

Eligibility Criteria

Sex: All

Age: 12 - 70+

Healthy Volunteers: Not accepted

Interventions

Tezepelumab

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-29. This information was provided to ClinicalTrials.gov by AstraZeneca on 2025-03-25.